Highlights Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-23 pm EST			5-day change	1st Jan Change
220.14 ^USD	+0.76%		+0.68%	+6.37%

Jan. 23	Argus Raises Price Target on Johnson & Johnson to $240 From $210	MT
Jan. 23	Bernstein Adjusts Price Target on Johnson & Johnson to $225 From $208, Maintains Market Perform Rating	MT

Highlights

Jan. 22	Johnson & Johnson Reports Modest Q4 Beat but Stock Seems Fairly Valued, Morgan Stanley Says	MT
Jan. 21	Sector Update: Health Care Stocks Higher Late Afternoon	MT
Jan. 21	Wall Street jumps on Greenland framework deal	RE
Jan. 21	Sector Update: Health Care	MT
Jan. 21	Top Midday Stories: Trump Says US Doesn't Want to Use Force to Acquire Greenland; Netflix Shares Fall on Low Q1 Guidance	MT
Jan. 21	Global markets live: Netflix, OpenAI, Nvidia, Meta, Alibaba, Netflix…
Jan. 21	When America Starts to Feel Like a Risky Asset
Jan. 21	Wall St set to extend losses, eyes on Trump's speech at Davos	RE
Jan. 21	Sector Update: Health Care	MT
Jan. 21	Johnson & Johnson Issues Upbeat 2026 Sales Outlook; Fourth-Quarter Earnings Meet Street Views	MT
Jan. 21	Johnson & Johnson Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
Jan. 21	Stocks Down Pre-Bell After Recording Biggest Drop Since October	MT
Jan. 21	Johnson & Johnson Provides Sales Guidance for the Full Year of 2026	CI
Jan. 21	Johnson & Johnson's Fiscal Q4 Adjusted Earnings, Sales Rise; Sets Fiscal 2026 Outlook	MT
Jan. 21	J&J CFO says 2026 guidance includes "hundreds of millions of dollars" impact from MFN deal with Trump administration	RE
Jan. 21	(JNJ) Johnson & Johnson Expects 2026 Adjusted EPS Range $11.43 - $11.63, vs. FactSet Est of $11.48	MT
Jan. 21	(JNJ) Johnson & Johnson Expects 2026 Reported Sales Range $100B - $101B	MT
Jan. 21	Earnings Flash (JNJ) Johnson & Johnson Reports Q4 Revenue $24.56B, vs. FactSet Est of $24.15B	MT
Jan. 21	Earnings Flash (JNJ) Johnson & Johnson Posts Q4 Adjusted EPS $2.46 per Share, vs. FactSet Est of $2.46	MT
Jan. 21	J&J sees 2026 profit above Wall Street estimates despite tariffs hit, Trump pricing deal	RE
Jan. 20	Experts can testify about suspected J&J talc products' cancer link, special master recommends	RE
Jan. 20	U.S. judge allows experts to testify that talc products cause cancer in J&J cases	RE
Jan. 20	U.S. judge allows experts to testify that talc products caused cancer in J&J cases	RE
Jan. 20	Stocks Fall as Investors Assess Trump's Tariff Announcement, Await Earnings	MT
Jan. 16	H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

J&J CFO Wolk on Orthopedics Spinoff, Earnings, Drug Pricing

October 14, 2025 at 12:20 pm EDT

Johnson & Johnson: A Dose of Resilience Amid Trade Tensions

April 15, 2025 at 09:53 am EDT